Abstract
This study describes the acceptability of a rectal microbicide gel formulation using dapivirine (DPV) among men and women from two countries (United States and Thailand) participating in the Microbicide Trials Network-026 trial. We evaluated participants’ acceptability of a rectal DPV/placebo gel as part of a Phase I trial (N = 26; 18 male, 8 female). Participants reported favorable acceptability of the study gel, with most participants reporting that they liked the gel the same (n = 14; 53.8%) or more (n = 11; 42.4%) than when they started the trial. Over half of participants noted that they would prefer the gel over condoms (n = 13; 50%) or that they liked condoms and the gel equally (n = 8; 30.8%). Side effects across products included leakage (n = 8; 30.8%), diarrhea (n = 4; 15.4%), or soiling (n = 1; 3.8%). The high acceptability of a rectal gel underscores its promise as a short-acting biomedical prevention, warranting future research for HIV prevention. Trial Registration: NCT03239483.
Original language | English (US) |
---|---|
Pages (from-to) | 1333-1346 |
Number of pages | 14 |
Journal | AIDS and behavior |
Volume | 26 |
Issue number | 5 |
DOIs | |
State | Published - May 2022 |
Keywords
- Dapivirine
- HIV
- HIV prevention
- Microbicides
- Rectal
ASJC Scopus subject areas
- Public Health, Environmental and Occupational Health
- Infectious Diseases
- Social Psychology